Results 11 to 20 of about 170,023 (183)

An update on Peginterferon beta-1a Management in Multiple Sclerosis: results from an interdisciplinary Board of German and Austrian Neurologists and dermatologists

BMC Neurology, 2019
Background Interferon (IFN) beta drugs have been approved for the treatment of relapsing forms of multiple sclerosis (RMS) for more than 20 years and are considered to offer a favourable benefit-risk profile. In July 2014, subcutaneous (SC) peginterferon
Annette Kolb-Mäurer, Cord Sunderkötter, Borries Kukowski, Sven G. Meuth, on behalf of the members of an expert meeting   +4 more
doaj   +1 more source

Persistence, adherence, healthcare resource utilisation and costs for interferon Beta in multiple sclerosis: a population-based study in the Campania region (southern Italy)

BMC Health Services Research, 2020
Background To differentiate five formulations of Interferon Beta for the treatment of multiple sclerosis (MS) in clinical practice, by analysing persistence, adherence, healthcare resource utilisation and costs at population level.
Marcello Moccia, Ilaria Loperto, Roberta Lanzillo, Antonio Capacchione, Antonio Carotenuto, Maria Triassi, Vincenzo Brescia Morra, Raffaele Palladino   +7 more
doaj   +1 more source

Prospective study of thyroid functions in multiple sclerosis patients treated with interferon beta in Alexandria University MS clinic

The Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2021
Background The incidence of thyroid dysfunction in multiple sclerosis (MS) patients on interferon (as a disease-modifying line) has been reported in many studies performed on patients already on interferon therapy.
Farouk Talaat, Hany Eldeeb
doaj   +1 more source

A Minimally Invasive Method for the Treatment of Post-Traumatic Disorders of the Bone Union of the Tibia

Acta Biomedica Scientifica, 2020
Background. The ability to control regeneration processes is a key link in the development of methods for treating patients with post-traumatic disorders of reparative osteogenesis. Aim of the study.
V. F. Lebedev, L. A. Dmitriyeva, I. A. Shuruguna, P. N. Khaziyev   +3 more
doaj   +1 more source

Interferon Beta: Analysis of Information on Adverse Reactions and Evaluation of Possibility of Signal Identification

Безопасность и риск фармакотерапии, 2019
Multiple sclerosis is  one  of  the  most common neurological diseases of  working age population. The last 20 years widely use drugs that change the  course of multiple sclerosis.
K. E. Zatolochina, I. I. Snegireva, A. S. Kazakov, V. K. Lepakhin   +3 more
doaj   +1 more source

Immunomodulatory activity of interferon‐beta [PDF]

Annals of Clinical and Translational Neurology, 2014
AbstractMultiple sclerosis (MS) is a complex disorder of the central nervous system that appears to be driven by a shift in immune functioning toward excess inflammation that results in demyelination and axonal loss. Beta interferons were the first class of disease‐modifying therapies to be approved for patients with MS after treatment with this type I
Kasper, Lloyd H, Reder, Anthony T
openaire   +2 more sources

Comparison Effect of Prescription Drugs on the Occurrence and the Number of Attacks in Patients with Multiple Sclerosis

مجله دانشکده پزشکی اصفهان, 2018
Background: Treatment has a major effect on attacks in patients with multiple sclerosis (MS). This study aimed to determine the effect of the type of used drug on occurrence and number of attacks in patients with multiple sclerosis.
Marjan Jamalian, Vahid Shaygannejad, Soleiman Kheiri, Morteza Sedehi, Omid Mirmosayyeb   +4 more
doaj   +1 more source

Beta interferons in clinically isolated syndromes: a meta-analysis Interferons beta nas síndromes clínicas isoladas: meta-análise

Arquivos de Neuro-Psiquiatria, 2008
Beta-interferon use in definite multiple sclerosis (MS) has been proven to modify clinical and magnetic resonance imaging outcome. We review and summarize the data of published double-blind, randomized clinical trials to assess, with a meta-analysis the ...
Ailton Melo, Bernardo Rodrigues, Amit Bar-Or   +2 more
doaj   +1 more source

The interferon beta therapies for treatment of relapsing–remitting multiple sclerosis: are they equally efficacious? A comparative review of open-label studies evaluating the efficacy, safety, or dosing of different interferon beta formulations alone or in combination

Therapeutic Advances in Neurological Disorders, 2011
Interferon beta preparations are the most widely used initial therapies prescribed for patients with relapsing–remitting multiple sclerosis. Phase III studies have demonstrated comparable efficacy on clinical measures of disease activity, variable ...
Volker Limmroth, Norman Putzki, Norman J. Kachuck   +2 more
doaj   +1 more source

Investigating the Occurrence of Femoral Head Avascular Necrosis in Patient with Multiple Sclerosis Treated with Interferon-Beta

مجله دانشکده پزشکی اصفهان, 2018
Background: Multiple sclerosis (MS) is a demyelinating inflammatory disease of central nervous system. Avascular necrosis (AVN) of femoral head is reported as an unusual complaint of multiple sclerosis.
Pegah Sadat Fatehi, Masoud Etemadifar
doaj   +1 more source